Look back at pharma news in week to September 7

9 September 2018

By Barbara Obstoj-Cardwell. Editor

Following the recent warnings on SGLT2 diabetes drug risks from the US Food and Drug Administration, analysts suggest this could benefit Danish firm Novo Nordisk. Also on the regulatory front, Hutchison China MediTech’s approval in China of Elunate for colorectal cancer was seen as big news for the company. Last week, Japan’s Shionogi announced the launch of its thrombocytopenia drug Mulpleta in the USA, setting up a pricing war with Dova. Also of note, NHS England took a big leap into CAR-T therapy by allowing patient access to Novartis’ Kymriah.

Novo Nordisk could benefit from latest FDA warning

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK